doi: 10.1161/CIRCULATIONAHA.106.647503
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2007;115:1537-1543.)
© 2007 American Heart Association, Inc.
Epidemiology |
Circulating Adipocyte–Fatty Acid Binding Protein Levels Predict the Development of the Metabolic Syndrome
A 5-Year Prospective Study
From the Department of Medicine (A.X., A.W.K.T., B.M.Y.C., N.M.S.W., C.H.Y.F., D.C.Y.Y., K.S.L.L.), Research Centre of Heart, Brain, Hormone, and Healthy Aging (A.X., B.M.Y.C., Y.W., K.S.L.L.), and Genome Research Centre (Y.W., P.C.S.), University of Hong Kong, and Department of Clinical Biochemistry (E.D.J.), Queen Mary Hospital, Hong Kong, China. Dr Janus is now with the Department of Medicine, University of Melbourne, Western Hospital, Footscray, Australia.
Correspondence to Dr Karen Lam, Department of Medicine, University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Rd, Hong Kong, China. E-mail ksllam{at}hkucc.hku.hk
Received June 22, 2006; accepted January 9, 2007.
Background— Adipocyte–fatty acid binding protein (A-FABP), a major cytoplasmic protein in adipocytes, plays a central role in the development of diabetes and atherosclerotic cardiovascular disease in experimental animals. We have previously shown that A-FABP is present in the bloodstream and that its circulating levels correlate with metabolic risk factors in a cross-sectional study. In the present study, we further evaluated the prospective association of A-FABP with the metabolic syndrome (MetS) as defined by the updated National Cholesterol Education Program criteria.
Methods and Results— In the present study, 495 nondiabetic adults from the population-based Hong Kong Cardiovascular Risk Factor Prevalence Study were prospectively followed up for 5 years. The relationship of serum A-FABP with the MetS and its components was investigated. At baseline, high A-FABP levels were associated with the MetS (odds ratio, 4.0; 95% CI, 1.5 to 10.4; highest versus lowest sex-specific tertile, adjusted for age, body mass index, the homeostasis model assessment index for insulin resistance, C-reactive protein, and adiponectin, P=0.005). On long-term follow-up, subjects with higher baseline A-FABP levels had progressively worse cardiometabolic risk profile and increasing risk of the MetS. Among 376 subjects without the MetS at baseline, 50 had developed it at 5 years. Apart from the homeostasis model assessment index for insulin resistance (P=0.001), baseline A-FABP was the only independent predictor of the development of the MetS during the 5-year follow-up (odds ratio, 4.7; 95% CI, 1.8 to 11.9; highest versus lowest sex-specific tertile, P=0.001, adjusted for the homeostasis model assessment index for insulin resistance and body mass index). A-FABP was predictive of the MetS even after adjustment for each of its individual components.
Conclusions— Circulating A-FABP predicts the development of the MetS independently of adiposity and insulin resistance.
CLINICAL PERSPECTIVE
This article has been cited by other articles:
 |
|
 |
|
  D. C. Y. Yeung, K. S. L. Lam, Y. Wang, A. W. K. Tso, and A. Xu Serum Zinc-{alpha}2-Glycoprotein Correlates with Adiposity, Triglycerides, and the Key Components of the Metabolic Syndrome in Chinese Subjects J. Clin. Endocrinol. Metab., July 1, 2009; 94(7): 2531 - 2536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Hui, W. Zhu, Y. Wang, K. S. L. Lam, J. Zhang, D. Wu, E. W. Kraegen, Y. Li, and A. Xu Major Urinary Protein-1 Increases Energy Expenditure and Improves Glucose Intolerance through Enhancing Mitochondrial Function in Skeletal Muscle of Diabetic Mice J. Biol. Chem., May 22, 2009; 284(21): 14050 - 14057. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M.-s. Lui, J. C.-m. Lam, H. K.-F. Mak, A. Xu, C. Ooi, D. C.-l. Lam, J. C.-w. Mak, P. L. Khong, and M. S.-M. Ip C-Reactive Protein Is Associated With Obstructive Sleep Apnea Independent of Visceral Obesity Chest, April 1, 2009; 135(4): 950 - 956. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C-L. Lam, A. Xu, K. S-L. Lam, B. Lam, J. C-M. Lam, M. M-S. Lui, and M. S-M. Ip Serum adipocyte-fatty acid binding protein level is elevated in severe OSA and correlates with insulin resistance Eur. Respir. J., February 1, 2009; 33(2): 346 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E J Rhee, W Y Lee, C Y Park, K W Oh, B J Kim, K C Sung, and B S Kim The association of serum adipocyte fatty acid-binding protein with coronary artery disease in Korean adults Eur. J. Endocrinol., February 1, 2009; 160(2): 165 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 WRITING GROUP MEMBERS, D. Lloyd-Jones, R. Adams, M. Carnethon, G. De Simone, T. B. Ferguson, K. Flegal, E. Ford, K. Furie, A. Go, et al. Heart Disease and Stroke Statistics--2009 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation, January 27, 2009; 119(3): e21 - e181. [Full Text] [PDF]
|
|
|
|
|
|
S. Kralisch, H. Stepan, J. Kratzsch, M. Verlohren, H.-J. Verlohren, K. Drynda, U. Lossner, M. Bluher, M. Stumvoll, and M. Fasshauer Serum levels of adipocyte fatty acid binding protein are increased in gestational diabetes mellitus Eur. J. Endocrinol., January 1, 2009; 160(1): 33 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hyun Koh, Y. Goo Shin, S. Min Nam, M. Young Lee, C. Hee Chung, and J. Yel Shin Serum Adipocyte Fatty Acid-Binding Protein Levels Are Associated With Nonalcoholic Fatty Liver Disease in Type 2 Diabetic Patients Diabetes Care, January 1, 2009; 32(1): 147 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C.Y. Yeung, Y. Wang, A. Xu, S. C.W. Cheung, N. M.S. Wat, D. Y.T. Fong, C. H.Y. Fong, M.T. Chau, P. C. Sham, and K. S.L. Lam Epidermal fatty-acid-binding protein: a new circulating biomarker associated with cardio-metabolic risk factors and carotid atherosclerosis Eur. Heart J., September 1, 2008; 29(17): 2156 - 2163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cabre, I. Lazaro, J. Girona, J. M. Manzanares, F. Marimon, N. Plana, M. Heras, and L. Masana Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes J. Lipid Res., August 1, 2008; 49(8): 1746 - 1751. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhang, D. C.Y. Yeung, M. Karpisek, D. Stejskal, Z.-G. Zhou, F. Liu, R. L.C. Wong, W.-S. Chow, A. W.K. Tso, K. S.L. Lam, et al. Serum FGF21 Levels Are Increased in Obesity and Are Independently Associated With the Metabolic Syndrome in Humans Diabetes, May 1, 2008; 57(5): 1246 - 1253. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Takata, H. Osawa, M. Kurata, M. Kurokawa, J. Yamauchi, M. Ochi, W. Nishida, T. Okura, J. Higaki, and H. Makino Hyperresistinemia Is Associated With Coexistence of Hypertension and Type 2 Diabetes Hypertension, February 1, 2008; 51(2): 534 - 539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cabre, I. Lazaro, J. Girona, J. M. Manzanares, F. Marimon, N. Plana, M. Heras, and L. Masana Plasma Fatty Acid-Binding Protein 4 Increases with Renal Dysfunction in Type 2 Diabetic Patients without Microalbuminuria Clin. Chem., January 1, 2008; 54(1): 181 - 187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W.K. Tso, A. Xu, P. C. Sham, N. M.S. Wat, Y. Wang, C. H.Y. Fong, B. M.Y. Cheung, E. D. Janus, and K. S.L. Lam Serum Adipocyte Fatty Acid Binding Protein as a New Biomarker Predicting the Development of Type 2 Diabetes: A 10-year prospective study in a Chinese cohort Diabetes Care, October 1, 2007; 30(10): 2667 - 2672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.C.Y. Yeung, A. Xu, C.W.S. Cheung, N.M.S. Wat, M.H. Yau, C.H.Y. Fong, M.T. Chau, and K.S.L. Lam Serum Adipocyte Fatty Acid-Binding Protein Levels Were Independently Associated With Carotid Atherosclerosis Arterioscler. Thromb. Vasc. Biol., August 1, 2007; 27(8): 1796 - 1802. [Abstract] [Full Text] [PDF]
|
|